Glycemic Control Parameter   HbA1c, % (95% CI) Fasting Plasma Glucose, mg/dl (95% CI)   Adjusted for baseline glycemic measure†     Bromocriptine-QR -0.62 (-0.90, -0.34) -10.4 (-21.9, 1.1) Placebo 0.04 (-0.33, 0.42) 4.6 (-10.7, 19.9) Between group difference -0.66 (-1.13, -0.19); p < 0.01 -15.0 (-34.1, 4.1); p = 0.12 Fully adjusted model‡     Bromocriptine-QR -0.67 (-0.96, -0.39) -12.7 (-24.1, -1.3) Placebo 0.14 (-0.24, 0.52) 8.7 (-6.6, 24.1) Between group difference -0.81 (-1.30, -0.33); p =0.001 -21.5 (-41.0, -1.9); p = 0.04 *ITTm analysis: modified intent to treat – all subjects treated that had one post randomization laboratory measure, missing week values of HbA1c and fasting plasma glucose were handled using the last observation carried forward method †Adjusted for baseline glycemic measure: Model controlled for baseline HbA1c for the HbA1c outcome and for baseline Fasting Plasma Glucose for the Fasting Plasma Glucose outcome ‡Fully adjusted model: Model controlled for baseline glycemic measures (% for HbA1c and mg/dL for fasting glucose), age (years), race/ethnicity (white, black, Hispanic, other), presence of concurrent oral antihyperglycemic medication (yes/no), whether the dose of antihyperglycemic medication was adjusted during follow-up (increase, decrease, same), whether additional antihyperglycemic medication was added during follow-up (yes/no), baseline rosiglitazone equivalent dose (mg), and the duration of diabetes mellitus (years)

Table 2: Effect of Bromocriptine-QR on Change from baseline to week 52 for HbA1c and Fasting Plasma Glucose (ITTm) among Subjects with Baseline A1c of ≥ 7.5*.